
    
      Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
      be treated successfully with the conventional CHOP regimen. Apatinib is a small-molecule
      multitargeted tyrosine kinase inhibitor. The investigators have been proceeding this trial to
      evaluate the efficacy and safety of the Apatinib Combined With CHOP Regimen(cyclophosphamide,
      vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell
      lymphoma.
    
  